Aurinia Pharmaceuticals Inc AUPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 9:04 AM EDT
11.00quote price arrow down-0.21 (-1.87%)
Volume
588
Close
11.21quote price arrow down-0.24 (-2.10%)
Volume
1,630,940
52 week range
8.86 - 33.97
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.21
  • 52 Week High33.97
  • 52 Week High Date11/03/21
  • 52 Week Low8.86
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap1.589B
  • Shares Out141.74M
  • 10 Day Average Volume3.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-50.98

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close11.21
  • 52 Week High33.97
  • 52 Week High Date11/03/21
  • 52 Week Low8.86
  • 52 Week Low Date05/09/22
  • Market Cap1.589B
  • Shares Out141.74M
  • 10 Day Average Volume3.11M
  • Dividend-
  • Dividend Yield-
  • Beta1.04
  • YTD % Change-50.98

RATIOS/PROFITABILITY

  • EPS (TTM)-1.27
  • P/E (TTM)-8.80
  • Fwd P/E (NTM)-15.55
  • EBITDA (TTM)-165.246M
  • ROE (TTM)-41.11%
  • Revenue (TTM)66.32M
  • Gross Margin (TTM)98.04%
  • Net Margin (TTM)-253.66%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aurinia Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a...
George Milne Ph.D.
Independent Chairman of the Board
Peter Greenleaf
President, Chief Executive Officer, Director
Joe Miller
Chief Financial Officer
Robert Huizinga Ph.D.
Executive Vice President - Research
Matthew Donley
Executive Vice President, Operations and Strategy
Address
1203-4464 Markham St
Victoria, BC
V8Z 7X8
Canada

Top Peers

SYMBOLLASTCHG%CHG
BLU
BELLUS Health Inc
8.80UNCHUNCH
ABUS
Arbutus Biopharma Corp
2.31-0.10-4.15%
TH
Target Hospitality Corp
6.05-0.17-2.73%
MRTX
Mirati Therapeutics Inc
57.68-2.31-3.85%
APS